Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry.
Dilute-and-shoot
High resolution mass spectrometry
Liquid chromatography
Meldonium
Screening method
Solid-phase extraction
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
20 Feb 2021
20 Feb 2021
Historique:
received:
23
09
2020
revised:
09
12
2020
accepted:
21
12
2020
pubmed:
17
1
2021
medline:
22
6
2021
entrez:
16
1
2021
Statut:
ppublish
Résumé
Considering the huge amount of substances associated with athletic performance improvement, current doping control analysis requires a comprehensive screening method, which leads to the detection of prohibited substances of different physico-chemical properties. This comprehensiveness associated with instrumental approaches based on high resolution mass spectrometry has allowed the development of extremely sensitive and selective detection methods. Furthermore, it is desirable the method to be simple, fast and straightforward. Mildronate is a highly polar quaternary amine, classified as metabolic modulator by the World Anti-Doping Agency (WADA). The inclusion of mildronate in the screening strategy is a challenge considering its singular physicochemical properties, compared to numerous doping agents of low and medium polarity. For this purpose, a method combining solid-phase extraction (SPE) and dilute-and-shoot approach has been developed and validated, allowing the detection of mildronate and other 332 prohibited substances. In the sample preparation protocol, the enzymatic deconjugation step and SPE conditions were stressed to enable the recovery of mildronate without jeopardizing the detection of other doping agents. The C
Identifiants
pubmed: 33453569
pii: S0731-7085(20)31757-X
doi: 10.1016/j.jpba.2020.113870
pii:
doi:
Substances chimiques
Methylhydrazines
0
3-(2,2,2-trimethylhydrazine)propionate
73H7UDN6EC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113870Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no competing interests.